Compounded dermatology medications give dermatology practices an option when a commercially available medication does not adequately meet a patient’s individual needs. Instead of dispensing a standard manufactured product, a compounding pharmacy can prepare a medication according to a specific prescription and formulation when the applicable requirements are satisfied. This can be useful when a patient needs a different strength, dosage form, combination of active ingredients, or formulation characteristics that are not commercially available. FDA explains that compounded drugs can serve an important medical need, but they are not FDA-approved products and must be prepared within the applicable legal and professional framework.
For dermatology practices, the concept is particularly relevant because skin conditions can vary significantly from one patient to another. One patient may need a topical formulation that combines multiple ingredients, while another may need a different concentration or dosage form because of intolerance to an ingredient in a commercially available product. However, customization should never be confused with unlimited formulation freedom. The pharmacy still needs to follow applicable requirements for prescriptions, ingredients, compounding procedures, and quality. This guide explains how compounded dermatology medications work, where they may fit into dermatology practice, and what providers should consider when choosing a compounding pharmacy.
What Are Compounded Dermatology Medications?
Compounded dermatology medications are customized preparations made by a compounding pharmacy according to a prescription and the patient’s specific clinical needs. They may be prepared as creams, ointments, gels, lotions, solutions, capsules, or other dosage forms depending on the medication and prescription. The purpose is generally to create a formulation that addresses a need that cannot be adequately met by a commercially available product. Under Section 503A, compounding by a state-licensed pharmacy generally involves a valid prescription for an identified individual patient.
The idea is similar to tailoring clothing rather than buying something directly off the rack. A commercially manufactured medication is designed for a broad patient population, while a compounded preparation can be customized when there is a legitimate patient-specific reason to do so. That might involve changing the dosage form, adjusting the strength, combining ingredients when appropriate, or removing an ingredient that a patient cannot tolerate. The exact options depend on the prescription, the ingredients involved, the pharmacy’s capabilities, and the applicable regulations.
This distinction is important because the word “compounded” does not mean “stronger,” “better,” or automatically more effective. It simply describes how the medication is prepared. The clinical value comes from whether the customized formulation addresses a legitimate patient need that cannot be adequately met by an available commercial product.
Why Dermatology Practices Use Compounded Medications
Dermatology practices may use compounded medications when customization provides a practical clinical advantage for an individual patient. Skin conditions can involve different areas of the body, different severities, different tolerability issues, and different treatment preferences, so one standardized formulation may not always be appropriate for every patient. A compounded medication can sometimes allow the prescriber and pharmacist to work toward a formulation that better fits the patient’s particular circumstances.
For example, a patient may have difficulty tolerating an inactive ingredient found in a commercially available topical product. Another patient may need a combination of active ingredients in one preparation rather than applying several separate products. In other situations, the issue may be dosage form: a patient may have a reason to use a cream, gel, lotion, or another formulation rather than the commercially available form. These situations illustrate why dermatology is a field where customized medication preparation can have a useful role.
Still, the presence of a clinical preference does not automatically justify compounding. FDA’s 503A framework restricts compounding of drugs that are essentially copies of commercially available products under specified circumstances. FDA’s guidance explains that a compounded drug should not simply be routinely substituted for a commercially available product without the circumstances required by the law.
Common Types of Compounded Dermatology Medications
Compounded dermatology medications can take many forms, but topical preparations are among the most relevant for dermatology practices. Depending on the prescription and applicable requirements, a compounding pharmacy may prepare creams, ointments, gels, lotions, solutions, or other formulations. The exact formulation is determined by the patient’s needs and the prescriber’s instructions rather than by a universal list of products available from every pharmacy.
Common categories may include customized preparations used in areas such as acne management, hyperpigmentation, inflammatory skin conditions, irritation, and other dermatologic concerns. Some practices may also work with pharmacies on formulations involving multiple active ingredients or different concentrations when an appropriate commercial alternative does not meet the patient’s needs. The important point is that the medication should be considered on a case-by-case basis rather than assuming that a compounded formulation is automatically appropriate for a particular diagnosis.
A dermatology practice should also distinguish between a medication’s active ingredients and its formulation. Two products may contain similar active ingredients but behave differently because of their vehicle, concentration, dosage form, or other formulation characteristics. That is one reason provider-pharmacy communication is so important when developing customized dermatology preparations.
Compounded Topical Medications for Dermatology
Compounded topical medications can allow dermatology providers to customize the vehicle, strength, or combination of ingredients when legally and clinically appropriate. Topical compounding may involve creams, gels, ointments, lotions, or solutions designed for application to the skin. The formulation can matter because the vehicle influences how a medication is applied and experienced by the patient, while the prescribed concentration determines the amount of active ingredient in the preparation.
For dermatology practices, this can be particularly useful when patients have different tolerability requirements. Some patients may prefer a lighter formulation, while others may require a different vehicle for a particular body area or treatment plan. A pharmacist can work from the prescription to prepare the formulation according to the specified requirements rather than relying on a one-size-fits-all commercial product.
However, topical does not mean risk-free. FDA has issued safety communications concerning certain compounded topical products, including an April 2025 alert concerning potential risks associated with compounded topical finasteride products. This is a useful reminder that customized topical medications still require appropriate prescribing, formulation, labeling, patient counseling, and quality controls. Dermatology practices should therefore evaluate the pharmacy and formulation rather than assuming that topical compounding requires little regulatory or clinical attention.
Common Dermatology Conditions Treated With Compounded Medications
Compounded medications may be considered across a range of dermatologic conditions when an individualized formulation is medically appropriate. Depending on the patient’s condition and prescription, dermatology compounding may be used for customized preparations related to acne, inflammatory skin conditions, pigmentation concerns, and other specialized treatment needs. The specific ingredients and combinations should always be determined by the prescribing clinician and the pharmacy based on the patient’s circumstances and applicable regulations.
The potential advantage is flexibility rather than a guaranteed improvement in treatment outcomes. For example, if a patient cannot tolerate an ingredient in a commercially available formulation, a pharmacist may be able to prepare a suitable alternative when the prescription and regulatory requirements permit it. Likewise, when several compatible ingredients are clinically appropriate and can legally be combined, a customized formulation may simplify the patient’s topical routine.
This is also where practices should avoid making broad marketing claims. A compounded dermatology medication should not be described as automatically more effective than an FDA-approved commercial product. FDA emphasizes that compounded drugs do not undergo the agency’s premarket review for safety, effectiveness, and quality. The strongest rationale for compounding is therefore a legitimate patient-specific need, not the assumption that customization itself guarantees better results.
How a Dermatology Prescription Is Compounded
The compounding process starts with the prescription and the pharmacy’s review of the formulation requirements. The pharmacist needs enough information to understand what medication is being requested, including the ingredients, strength, dosage form, quantity, directions, and other relevant prescription details. The pharmacy then evaluates the formulation and ingredients before preparing the medication according to its procedures and applicable requirements.
Ingredient sourcing is an important part of this process. FDA states that 503A compounders may only use bulk drug substances that meet specific requirements, including applicable USP or National Formulary monographs, being components of FDA-approved drug products under specified conditions, or appearing on the FDA’s 503A bulks list when the relevant requirements are met. FDA also states that bulk substances must be accompanied by a valid certificate of analysis and come from an establishment registered with FDA under Section 510.
The process does not end when the formulation is mixed. Appropriate labeling, documentation, quality procedures, storage information, and communication with the prescriber are all important parts of responsible compounding. For a dermatology practice, having a clear prescription workflow can make the relationship much more efficient and reduce avoidable questions or delays.
503A Rules for Compounded Dermatology Medications
Many pharmacy-based customized dermatology preparations fall within the 503A framework when the applicable requirements are satisfied. Section 503A applies to human drug compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician who is not operating as a 503B outsourcing facility. Among other conditions, 503A generally requires compounding based on a valid prescription for an identified individual patient.
The 503A framework also includes restrictions on compounding medications that are essentially copies of commercially available drug products. FDA’s current guidance explains that a compounded drug may be considered essentially a copy when it contains the same active pharmaceutical ingredient or ingredients in the same, similar, or easily substitutable strength and can be used by the same route of administration, subject to the applicable exceptions and policies.
This matters for dermatology because a practice should not assume that any commercially available topical medication can simply be reproduced by a compounding pharmacy. There needs to be an appropriate basis for the compounded formulation under the applicable rules. A good pharmacy should be able to explain the regulatory basis for the preparation rather than simply accepting every requested formulation without review.
Are Compounded Dermatology Medications FDA-Approved?
No, compounded dermatology medications are not FDA-approved products. FDA explains that compounded drugs do not undergo the same premarket review for safety, effectiveness, and quality that FDA-approved medications undergo. That does not mean lawful compounding has no role in healthcare, but it does mean that providers should communicate accurately about what a compounded medication is and what FDA approval does and does not mean.
This distinction becomes particularly important when patients compare compounded medications with commercial products. An FDA-approved dermatology medication has gone through the FDA’s drug approval process for its specific indication, formulation, and conditions of use. A compounded medication is prepared for a particular clinical need under the applicable compounding framework and does not carry the same FDA approval status.
For providers, accurate communication protects both the patient and the practice. Statements such as “FDA-approved compounded cream” can be misleading because FDA does not approve compounded drugs in the same way it approves commercially manufactured medications. Instead, providers should describe the preparation accurately and explain why compounding is being considered when appropriate.
Safety and Quality Considerations
Quality control is one of the most important considerations when selecting a compounding pharmacy. FDA notes that compounded drugs can present risks because they do not undergo FDA premarket review and because problems with compounding practices can result in contaminated or otherwise poor-quality medications. FDA maintains inspection, recall, and risk-alert resources specifically to help identify problems involving compounded drugs.
For dermatology practices, quality considerations should include ingredient sourcing, formulation procedures, documentation, storage requirements, labeling, and appropriate quality assurance. The pharmacy should also have processes for reviewing prescriptions and identifying potential formulation problems before preparation. If a preparation involves sterile compounding, additional sterile-compounding requirements become relevant.
FDA’s current compounding risk alerts illustrate why practices should stay informed. In August 2026, FDA reminded compounders not to use dietary-supplement-grade glutathione for injectable preparations. The agency has also previously issued an alert concerning risks associated with compounded topical finasteride. These examples reinforce a simple point: the quality of the ingredient and the way a medication is compounded matter just as much as the name of the active ingredient.
Compounded Dermatology Medications vs Commercial Products
The choice between a compounded dermatology medication and a commercially manufactured product should be based on the patient’s needs rather than the assumption that one category is universally superior. Commercial medications benefit from FDA premarket review, standardized manufacturing, and established labeling. Compounded medications offer customization but do not undergo the same FDA approval process. The right option depends on whether the patient has a legitimate need that cannot be adequately addressed by an available commercial product.
| Factor |
Compounded Dermatology Medication |
Commercial FDA-Approved Product |
| Customization |
Can be customized when appropriate |
Standardized formulation |
| FDA premarket approval |
No |
Yes |
| Patient-specific prescription |
Generally required for 503A |
Depends on the medication |
| Formulation flexibility |
Potentially greater |
Fixed commercial formulation |
| Quality review |
Pharmacy and applicable regulatory standards |
FDA premarket review plus manufacturing requirements |
| Best use case |
Specific patient need not adequately met by available product |
Standard treatment where an appropriate product is available |
This comparison should not be interpreted as a recommendation for one category over the other. FDA specifically recognizes that compounded drugs can serve an important medical need while also explaining that they carry different risks from FDA-approved products. For dermatology practices, the key question should be whether compounding solves a genuine formulation or patient-specific problem.
How Dermatology Practices Can Choose a Compounding Pharmacy
Choosing a compounding pharmacy should involve more than comparing price or turnaround time. Dermatology practices should evaluate the pharmacy’s licensing, compounding capabilities, ingredient sourcing, quality procedures, prescription workflow, provider communication, and experience with dermatologic formulations. A pharmacy that works regularly with dermatology practices may also understand the practical differences between topical vehicles and the information providers need to include in prescriptions.
A useful evaluation starts with basic questions. Is the pharmacy properly licensed in the relevant states? Does it clearly explain whether it operates under 503A or another regulatory framework? Can it explain where its bulk ingredients come from and what documentation accompanies them? Does it have established procedures for quality assurance and prescription review?
Practices should also look at how the pharmacy communicates. If a pharmacist has a question about a formulation, there should be a straightforward way for the prescriber to discuss it. That kind of communication can be particularly valuable when a prescription involves multiple ingredients, a specialized dosage form, or a formulation that requires clarification.
For additional guidance, practices can review Emerald’s resources on dermatology compounding pharmacy and custom skincare formulations for dermatology practices.
Why Provider-Pharmacy Communication Matters
Good communication between a dermatology provider and compounding pharmacist can make customized medication preparation more accurate and efficient. A prescription may contain multiple formulation details, and the pharmacist may need clarification about strength, dosage form, quantity, directions, or the intended application site. When the pharmacy has a clear communication process, questions can be resolved before the medication is prepared rather than creating delays after the prescription has already entered the workflow.
This relationship is especially useful when a practice frequently prescribes customized formulations. Over time, the pharmacy can become familiar with the practice’s prescription patterns and communication preferences while still reviewing each prescription according to applicable professional and regulatory requirements. The relationship should remain centered on the individual patient’s needs rather than becoming an automatic process for reproducing the same formulation regardless of clinical circumstances.
For dermatology practices, this can also support better coordination between the prescriber, pharmacist, and patient. Patients may have questions about how to apply a topical medication, how it should be stored, or how the compounded formulation differs from a commercial product. Clear instructions and consistent communication can help reduce confusion and make the treatment process easier to follow.
What to Know Before Prescribing a Compounded Dermatology Medication
Before prescribing a compounded dermatology medication, providers should confirm that there is a legitimate patient-specific reason for compounding and that the formulation is appropriate under the applicable rules. The provider should have a clear understanding of the desired active ingredients, strength, dosage form, quantity, directions, and any relevant patient considerations. If the formulation is unusual or contains multiple active ingredients, communication with the compounding pharmacist can help identify potential issues before preparation.
Providers should also remember that compounded medications are not automatically interchangeable with commercial products. A compounded formulation should have a clear clinical rationale, and the pharmacy should have an appropriate regulatory basis for preparing it. FDA’s current guidance and bulk-substance requirements should be considered when questions arise about specific ingredients or formulations.
A practical checklist for dermatology practices includes:
- Confirm the patient’s specific clinical need.
- Determine whether a suitable commercial product already meets that need.
- Provide complete prescription instructions.
- Confirm the pharmacy’s licensing and compounding framework.
- Ask about ingredient sourcing when appropriate.
- Understand applicable quality and USP standards.
- Establish a clear provider-pharmacist communication process.
- Give the patient appropriate instructions for use and storage.
Taking these steps makes compounding a deliberate clinical decision rather than simply an alternative way to obtain a medication.
Conclusion
Compounded dermatology medications can provide valuable customization when a commercially available product does not adequately meet an individual patient’s needs. Topical creams, gels, ointments, lotions, and other formulations can be prepared according to a prescription when the pharmacy and preparation meet the applicable requirements. For dermatology practices, the greatest advantage is flexibility, but that flexibility comes with the responsibility to select appropriate formulations, use qualified pharmacy partners, and communicate accurately about the regulatory status of compounded drugs.
FDA’s current guidance makes several points particularly important: 503A compounding generally requires a valid prescription for an identified patient, bulk drug substances must meet specific requirements, and compounded drugs are not FDA-approved products.
For providers, the best approach is straightforward: identify the patient need, evaluate whether compounding is appropriate, choose a qualified pharmacy, and maintain clear communication throughout the process. When those pieces work together, compounded dermatology medications can serve as a practical option for individualized care without confusing customization with FDA approval or assuming that every formulation is appropriate for every patient.
FAQs About Compounded Dermatology Medications
Are compounded dermatology medications safe?
Compounded dermatology medications can be appropriate when they are prescribed and prepared correctly, but they are not subject to the same FDA premarket review as FDA-approved drugs. Safety therefore depends on factors including the specific formulation, ingredient quality, pharmacy practices, prescription, and appropriate use. FDA maintains risk alerts and inspection information because poor-quality compounding can create significant patient risks.
Are compounded dermatology medications FDA-approved?
No. Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness, and quality before marketing in the same way it reviews FDA-approved medications. A compounded medication can still be prepared lawfully under the applicable federal and state framework when the required conditions are met.
What dermatology medications can be compounded?
The specific medications and formulations depend on the pharmacy, prescription, ingredients, and applicable regulations. Dermatology compounding may involve customized topical creams, ointments, gels, lotions, and other dosage forms. However, pharmacies cannot simply compound any formulation requested, and 503A rules place restrictions on ingredients and products that are essentially copies of commercially available medications.
Does a compounded dermatology medication require a prescription?
For a pharmacy operating under Section 503A, compounding generally occurs after receipt of a valid prescription for an identified individual patient. This patient-specific requirement is one of the central characteristics of the 503A framework. Other compounding pathways, such as 503B outsourcing facilities, operate under different requirements.
How should a dermatology practice choose a compounding pharmacy?
A practice should evaluate the pharmacy’s licensing, regulatory framework, ingredient sourcing, quality procedures, dermatology compounding capabilities, prescription workflow, and provider communication. It is also useful to ask how the pharmacy handles formulation questions and what standards apply to the preparation. Choosing a pharmacy should be based on the practice’s clinical requirements and the pharmacy’s ability to meet them consistently.
